Table 3.
The baseline medications of the patients
| Variable | TASC-A n=162(%) | TASC-B n=97(%) | TASC-C n=53(%) | TASC-D n=31(%) | P* |
|---|---|---|---|---|---|
| Antidiabetic | 56 (34.6) | 31 (32.0) | 18 (34.0) | 9 (29.0) | 0.928 |
| Statin | 49 (30.2) | 31 (32.0) | 23 (43.4) | 11 (35.5) | 0.353 |
| ACE-i/ARB | 66 (40.7) | 43 (44.3) | 26 (49.1) | 12 (38.7) | 0.698 |
| CCB | 62 (38.3) | 43 (44.3) | 24 (45.3) | 14 (45.2) | 0.684 |
| Beta blocker | 67 (41.4) | 40 (41.2) | 18 (34.0) | 8 (25.8) | 0.332 |
| Pentoxifylline | 92 (56.8) | 59 (60.8) | 31 (58.5) | 18 (58.1) | 0.939 |
| Cilastazol | 65 (40.1) | 49 (50.5) | 27 (50.9) | 15 (48.4) | 0.307 |
*
Chi-square test
ACE-i/ARB - angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CCB - calcium channel blocker; TASC - Trans Atlantic Inter-Society Consensus II class